Summary Keywords drug-repositioning, thyroid-cancer, anti-diabetic, metformin, diabetes Citation Greco A, Coperchini F, Croce L, Magri F, Teliti M and Rotondi M (2023) Drug repositioning in thyroid cancer treatment: the intriguing case of anti-diabetic drugs
Clinical trials from the National Institute of Mental Health indicate that 34% of patients with fatigue-predominant depression reported marked energy improvement after 4 to 8 weeks on sertraline , as summarized in this review of sertraline and energy improvement
Even though costs increase at higher doses, patients know what theyre getting and who is prescribing it
GHK-Cu (glycyl-L-histidyl-L-lysine bound to copper(II)) has been used for decades in low-concentration topical cosmetics with a generally favorable tolerability record, but there is almost no published human adverse-event data especially for injectable or systemic research use
Common and Distinct Adverse Effect Profiles Both tirzepatide and semaglutide share gastrointestinal adverse effects as the primary tolerability concern during dose escalation
Estrogens are synthesised from androgen substrates via the aromatase enzyme expressed in the brain, skin, ovary, adipose, bone and adrenal cortex
